Published in Cancer J on November 28, 2012
Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol (2014) 1.15
Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg (2013) 0.90
Preoperative high level of D-dimers predicts unresectability of pancreatic head cancer. World J Gastroenterol (2014) 0.87
Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Devel Ther (2015) 0.85
Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol (2015) 0.83
Surgical resection strategies for locally advanced pancreatic cancer. Langenbecks Arch Surg (2015) 0.81
Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. Mol Imaging Biol (2016) 0.77
HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer. Am J Transl Res (2015) 0.76
Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol (2016) 0.76
Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford) (2015) 0.76
Feasibility and reliability of pancreatic cancer staging using a new confocal non-fluorescent microscopy probe: a double-blind study in rats. Surg Endosc (2016) 0.75
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res (2008) 5.21
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology (2005) 4.96
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol (2004) 3.43
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg (2008) 3.36
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg (2004) 2.62
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Population-based study of islet cell carcinoma. Ann Surg Oncol (2007) 2.44
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer (2007) 2.40
Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol (2007) 2.40
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res (2003) 2.27
Intraductal papillary mucinous neoplasms of the pancreas: effect of invasion and pancreatic margin status on recurrence and survival. Ann Surg Oncol (2006) 2.12
Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res (2003) 2.11
Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery (2006) 2.09
Mesocaval shunting: a novel technique to facilitate venous resection and reconstruction and enhance exposure of the superior mesenteric and celiac arteries during pancreaticoduodenectomy. J Am Coll Surg (2013) 1.98
NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol (2004) 1.96
Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed pancreatic malignancy. Gastrointest Endosc (2008) 1.92
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid (2005) 1.89
Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg (2005) 1.84
The learning curve in pancreatic surgery. Surgery (2007) 1.84
Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) (2011) 1.82
Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer (2007) 1.70
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys (2002) 1.69
Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer (2005) 1.64
Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg (2003) 1.64
Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res (2003) 1.63
Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene (2003) 1.61
Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery (2003) 1.60
Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg (2003) 1.58
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol (2006) 1.53
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol (2006) 1.52
Novel applications of endo GIA linear staplers during pancreaticoduodenectomy and total pancreatectomy. Am J Surg (2003) 1.51
Mechanisms of proinflammatory cytokine-induced biphasic NF-kappaB activation. Mol Cell (2003) 1.49
Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery (2008) 1.49
Factors that influence parathyroid hormone half-life: determining if new intraoperative criteria are needed. JAMA Surg (2013) 1.48
The Frey procedure for chronic pancreatitis secondary to pancreas divisum. JAMA Surg (2013) 1.46
Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol (2003) 1.45
Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg (2014) 1.44
Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery (2011) 1.43
Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery (2002) 1.42
Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol (2002) 1.40
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther (2006) 1.39
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol (2010) 1.38
Carcinoid tumors of the duodenum. Surgery (2005) 1.37
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene (2002) 1.36
Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res (2006) 1.36
Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell (2007) 1.35
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist (2014) 1.34
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res (2005) 1.31
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Ultrasound Q (2006) 1.30
Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. J Biol Chem (2004) 1.30
Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis (2005) 1.29
Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer (2010) 1.28
Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg (2009) 1.27
Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer (2007) 1.26
Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery (2005) 1.26
Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol (2008) 1.26
Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer (2011) 1.24
Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol (2008) 1.24
Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg (2007) 1.24
Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys (2008) 1.23
High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2010) 1.23
Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res (2008) 1.22
Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol (2009) 1.21
Neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am (2004) 1.18
Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A (2014) 1.18
Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol (2005) 1.17
Surgical treatment of non-functioning pancreatic islet cell tumors. J Surg Oncol (2005) 1.16
Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer (2003) 1.16
Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin (2008) 1.16
Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg (2003) 1.16
Dietary mutagen exposure and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.15
Current diagnosis and management of unusual pancreatic tumors. Am J Surg (2008) 1.15
Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointest Endosc (2012) 1.14
XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gastroenterol (2007) 1.13
Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin Cancer Res (2002) 1.13
Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg (2005) 1.13
Diagnosis, staging, and surveillance of pancreatic cancer. AJR Am J Roentgenol (2003) 1.12
Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg (2008) 1.12
K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas (2007) 1.10
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer (2006) 1.09
Recent advances in thyroid cancer. Curr Probl Surg (2008) 1.09
NF-kappaB in pancreatic cancer. Int J Gastrointest Cancer (2003) 1.09
Venous resection in pancreatic cancer surgery. Best Pract Res Clin Gastroenterol (2006) 1.09
Parathyroid carcinoma: a 22-year experience. Head Neck (2004) 1.08
Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res (2009) 1.08
Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol (2009) 1.08
Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev (2006) 1.08
Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol (2009) 1.07